March 1, 2024

 

Clairvo Technologies Co., Ltd. (Headquarters: Chiyoda, Tokyo; CEO: Riichi Yamada, hereafter "Clairvo") has entered into an exclusive business alliance agreement with Shukun Technology Co., Ltd. (Headquarters: Beijing, People's Republic of China; CEO: Anna Ma, hereafter “Shukun”).

With the conclusion of the agreement, Shukun and Clairvo aim to obtain necessary regulatory approvals to market two products in Japan.

The two medical device programs developed by Shukun are a coronary angiography CT imaging support software (hereafter "Shukun CTA") and a circulatory dynamics analysis program (hereafter "Shukun CT-FFR").

In China, the two products have already obtained NMPA Class III certificates.

 

Shukun CTA is a medical device program that aids in the diagnosis of patients with ischemic heart disease by providing a variety of functions to evaluate coronary artery morphology using AI from CT images obtained by coronary CT angiography (CCTA).

Shukun CT-FFR is a deep-learning based program that processes information obtained from coronary CT angiography (CCTA) images and performs hemodynamic analysis to calculate coronary blood flow reserve ratio (FFR) to assist in the diagnosis of coronary artery stenosis.

These Shukun products are entirely software-driven, fully automated with no human intervention.

Based on the company's philosophy of "Innovation For Healthcare", Clairvo, together with Shukun, aims to contribute to the reduction of workloads of radiologists and physicians to improve their work efficiency by introducing these products to the Japanese market.

 

【About Shukun】

Shukun Technology is a world-leading healthcare AI provider. With roots in cardiac AI imaging, Shukun is spearheading AI innovations in all areas of medical imaging.

Shukun’s Digital Body platform consists of a comprehensive suite of more than 40 AI-powered products, covering more than 5 major organs, including heart, brain, chest, liver and MSK . Shukun’s products assist medical professionals throughout the patient’s journey, from screening, diagnosis, and treatment decisions to surgical planning and have been thoroughly validated and are already making a huge impact in everyday clinical settings.

As of year end 2023, Shukun have obtained 12 NMPA Class III, 14 NMPA Class II, 4 MDR CE, and 2 FDA approvals. With field-tested reliability and performance, Shukun’s products have been embedded into the workflows of over 3,000 hospitals and 1,000 health check-up centers in China and overseas.

For more information, visit https://en.shukun.net/.

 

Our press releases are intended to inform our stakeholders about our company in a fair and timely manner. While they may contain information about products or diseases, they are not intended as advertisements, promotions, purchase recommendations, or customer inducements.